Clinical trial evidence shows that people who have ponesimod have fewer relapses than people who have teriflunomide., according to NICE final draft guidance.

Cannabidiol (Epidyolex®) is recommended for use in patients two years of age and older, within NHS Wales.

The licence extension covers the treatment of chronic sialorrhoea in children and adolescents aged 2 to 17 years and weighing ≥12 kg.

Risdiplam is recommended in NICE draft guidance as part of a managed access agreement.

According to NICE draft guidance, short-term clinical evidence shows that cenobamate reduces the number of seizures. It also increases how many people stop having any seizures.

In draft guidance published today, NICE has recommended cenobamate (also called Ontozry, and made by Arvelle Therapeutics) as a treatment option for epilepsy.

This webinar, featuring an expert panel of speakers, aims to help healthcare professionals to understand what spinal muscular atrophy (SMA) is, how it presents, how to treat it, and why early detection, diagnosis and treatment are essential to children's outcomes.

Ofatumumab is accepted for restricted use within NHS Scotland.

Ozanimod's effect on the progression of disability is unclear and cost-effectiveness estimates are higher than what NICE normally considers an acceptable use of NHS resources, according to final guidance.

Treatment is restricted to patients in whom other formulations of vigabatrin are not suitable.

NICE has published final draft guidance recommending the treatment and final guidance is expected in July.